SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Sharck Soup
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bocor who wrote (34442)9/6/2001 9:06:36 AM
From: Frederick Langford  Read Replies (2) of 37746
 
IDPH had positive mention this morning at Lehman. They indicate that Zevalin will be reviewed by an FDA advisory panel on September 11. They feel that there is a 75% or greater of a positive outcome and forecast revenues from the product of $70 million in the first year. Additionally, the weaker dollar should help the Pharmaceutical areas. The sector currently has a 12% premium to the S&P and is undervalued if you compare it with the historical 27% premium for the group.

Fred
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News